Coloplast's profit up by 5% in Q1 2018/19.
M2 PHARMA-February 6, 2019-Coloplast's profit up by 5% in Q1 2018/19
(C)2019 M2 COMMUNICATIONS
Coloplast A/S (CPH:COLOB), a medical device and related services company, reported on Tuesday net profit of DKK991m, or EPS of DKK4.66, for the first quarter of 2018/19, from 1 October 2018 to 31 December 2018.
This was a 5% increase over net profit of DKK940m, or EPS of DKK4.42, in Q1 2017/18.
Revenues for the quarter were DKK4,321m, up by 9% as compared with DKK3,955m in Q1 of 2017/18. Organic growth in the quarter was 8%.
Organic growth rates in the business areas for the quarter were 8% in Ostomy Care, 8%, in Continence Care, 9% in Interventional Urology and 11% in Wound & Skin Care 11%.
Also, there was solid growth during the quarter across all geographical regions, in particular Europe with 6% organic growth, driven by new product launches including SenSura Mio Convex and SpeediCath Flex.
In addition, the company provided financial guidance for 2018/19 and continues to expect organic revenue growth of 8% at constant exchange rates and a reported growth in DKK of 8% to 9%.
Further, Coloplast has expands its SpeediCath portfolio with the launch of SpeediCath Navi, a hydrophilic catheter specifically designed for emerging markets. This product will be launched during 2019 and 2020.
Coloplast A/S is a Danish multinational company that develops, manufactures and markets medical devices and services related to ostomy, urology, continence, and wound care.
((Comments on this story may be sent to firstname.lastname@example.org))
|Printer friendly Cite/link Email Feedback|
|Article Type:||Financial report|
|Date:||Feb 6, 2019|
|Previous Article:||Pulmatrix Inc approves one for ten reverse common stock split.|
|Next Article:||Arrevus acquires fusidic acid from Melinta Therapeutics for undisclosed amount.|